Monopar Therapeutics Inc. Proceeds from Issuance or Sale of Equity
Monopar Therapeutics Inc. (MNPR) reported Proceeds from Issuance or Sale of Equity of $10.93 million for the 6-month period ending 2021-06-30, per its 10-Q filed 2021-08-12.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOrSaleOfEquity · last filed 2021-08-12
- 2021-06-30: Proceeds from Issuance or Sale of Equity 6 month $10.93M.
- 2020-06-30: Proceeds from Issuance or Sale of Equity 6 month $1.42M.
| Period end | Proceeds from Issuance or Sale of Equity 6 month |
|---|---|
| 2021-06-30 | $10.93M 10-Q · filed 2021-08-12 |
| 2020-06-30 | $1.42M 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |